The expanding frontier of hematopoietic cell transplantation

Cytometry Part B - Clinical Cytometry

Volumn 82 B, Issue 5, 2012, Pages 271-279

  Spitzer, Thomas R ^a   Dey, Bimalangshu R ^a   Chen, Yi Bin ^a   Attar, Eyal ^a   Ballen, Karen K ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

flow cytometry; graft vs host disease; graft vs tumor; hematopoietic cell transplantation

Indexed keywords

AZACITIDINE; BORTEZOMIB; BRENTUXIMAB VEDOTIN; CCAAT ENHANCER BINDING PROTEIN ALPHA; CD135 ANTIGEN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; DENILEUKIN DIFTITOX; ETANERCEPT; FLUDARABINE; HISTONE DEACETYLASE INHIBITOR; INTERLEUKIN 2; LENALIDOMIDE; MELPHALAN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NUCLEOPHOSMIN; PENTOSTATIN; PREDNISONE; RAPAMYCIN; RITUXIMAB; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ADD ON THERAPY; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; BLOOD BANK; BLOOD DONOR; BLOOD SAMPLING; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER INCIDENCE; CANCER PROGNOSIS; CANCER SURVIVAL; CHIMERA; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL PRACTICE; CORD BLOOD STEM CELL TRANSPLANTATION; CORTICOSTEROID THERAPY; CYTOGENETICS; DISEASE FREE SURVIVAL; DONOR LYMPHOCYTE INFUSION; DRUG MEGADOSE; FLOW CYTOMETRY; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HAPLOIDY; HEALTH PROGRAM; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LOW DRUG DOSE; MOLECULARLY TARGETED THERAPY; MYELODYSPLASTIC SYNDROME; NONHUMAN; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; REVIEW; TARGET CELL DESTRUCTION; TREATMENT INDICATION; TUMOR MICROENVIRONMENT; UMBILICAL CORD BLOOD;

ANIMALS; BLOOD BANKS; CORD BLOOD STEM CELL TRANSPLANTATION; FETAL BLOOD; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY; HUMANS;

EID: 84866020506     PISSN: 15524949     EISSN: 15524957     Source Type: Journal    
DOI: 10.1002/cyto.b.21034     Document Type: Review

References (74)

1. Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, Apperley J, Slavin S, Pasquini M, Sandmaier BM, et al. Defining the intensity of conditioning regimens: Working definitions. Biol Blood Marrow Transplant 2009; 15: 1628-1633.
2. Giralt S, Ballen K, Rizzo D, Bacigalupo A, Horowitz M, Pasquini M, Sandmaier B,. Reduced-intensity conditioning regimen workshop: Defining the dose spectrum. Report of a workshop convened by the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant 2009; 15: 367-369.
3. Spitzer TR,. Bone marrow transplantation. In:, Chabner BA, Lynch TJ Jr, Longo DL, editors. Harrison's Manual of Oncology. New York, NY: McGraw Hill Medical; 2007. pp 337-344.
4. Spitzer TR, McAfee S, Sackstein R, Colby C, Toh HC, Mutani P, Saidman S, Weyouth DW, Preffer F, Poliquin C, et al. The intentional induction of mixed chimerism and achievement of anti-tumor responses following non-myeloablative conditioning therapy and HLA-matched donor bone marrow transplantation for refractory hematologic malignancies. Biol Blood Marrow Transplant 2000; 6: 309-320.
5. Baron F, Storb R,. Current roles for allogeneic hematopoietic cell transplantation following nonmyeloablative or reduced-intensity conditioning. Clin Adv Hematol Oncol 2005; 3: 799-819.
6. Foss F, van Besien K,. Reduced-intensity and nonmyeloablative conditioning regimens. Cancer Treat Res 2009; 144: 209-232.
7. Aversa F, Terenzi A, Tabilio A, Falzetti F, Carotti A, Ballanti S, Felicini R, Facinelli F, Velardi A, Ruggeri L, et al. Full haplotype-mismatched hematopoietic stem-cell transplantation: A phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol 2005; 23: 3447-3454.
8. Luznik L, O'Donnell PV, Symons HJ, Chen AR, Leffell MS, Zahurak M, Gooley TA, Piantadosi S, Kaup M, Ambinder RF, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 2008; 14: 641-650.
9. Ballen KK, Koreth J, Chen YB, Dey BR, Spitzer TR,. Selection of optimal alternative graft source: Mismatched unrelated donor, umbilical cord blood, or haploidentical transplant. Blood 2012; 119: 1972-1980.
10. Sharabi Y, Sachs DH,. Mixed chimerism and permanent specific transplantation tolerance induced by a non-lethal preparative regimen. J Exp Med 1989; 169: 493-502.
11. Kawai T, Poncelet A, Sachs DH, Mauiyyedi S, Boskovic S, Wee SL, Ko DS, Bartholomew A, Kimikawa M, Hong HZ, et al. Long-term outcome and alloantibody production in a non-myeloablative regimen for induction of renal allograft tolerance. Transplantation 1999; 68: 1767-1775.
12. Spitzer TR, Sykes M, Tolkoff-Rubin N, Kawai T, McAfee SL, Dey BR, Ballen K, Delmonico F, Saidman S, Sachs DH, et al. Long term follow-up of recipients of combined HLA-matched bone marrow and kidney transplantation for multiple myeloma with end-stage renal disease. Transplantation 2011; 91: 672-676.
13. Kawai T, Cosimi AB, Spitzer TR, Tolkoff-Rubin N, Suthanthiran M, Saidman S, Shaffer J, Preffer FI, Ding R, Sharma V, et al. HLA-mismatched renal transplantation without maintenance immunosuppression. New Engl J Med 2008; 358: 53-361.
14. Sykes M, Preffer F, McAfee S, Saidman SL, Weymouth D, Andrews DM, Colby C, Sackstein R, Sachs DH, Spitzer TR,. Mixed lymphohaemopoietic chimerism and graft-versus-lymphoma effects after non-myeloablative therapy and HLA-mismatched bone-marrow transplantation. Lancet 1999; 353: 1755-1759.
15. Toh HC, Spitzer TR, Preffer F, Alexander SI, McAfee S, Dombkowski D, Clark JS, Colby C, Saidman S, Sackstein R, et al. Fluctuating lymphocytes chimerism, tolerance and anti-tumor response in a patient with refractory lymphoma receiving nonmyeloablative conditioning and haploidentical related allogeneic bone marrow transplant. Cytokines Cell Mol Ther 2002; 7: 43-47.
16. Loenecke C, Shaffer J, Alexander SI, Preffer F, Dombkowski D, Saidman SL, Dey B, McAfee S, Spitzer TR, Sykes M,. NK cell recovery, chimerism, function, and recognition in recipients of haploidentical hematopoietic cell transplantation following nonmyeloablative conditioning using a humanized anti-CD2 mAb, Medi-507. Exp Hematol 2003; 31: 911-923.
17. Shaffer J, Villard J, Means TK, Alexander S, Dombkowski D, Dey BR, McAfee S, Ballen KK, Saidman S, Preffer FI, et al. Regulatory T-cell recovery in recipients of haploidentical nonmyeloablative hematopoietic cell transplantation with a humanized anti-CD2 mAb, MEDI-507, with or without fludarabine. Exp Hematol 2007; 35: 1140-1152.
18. Locascio SA, Morlkata T, Chittenden M, Preffer FI, Dombkowski DM, Andreola G, Crisalli K, Kawai T, Saidman SL, Spitzer TR, et al. Mixed chimerism, lymphocyte recovery, and evidence for early donor-specific unresponsiveness in patients receiving combined kidney and bone marrow transplantation to induce tolerance. Transplantation 2010; 90: 1607-1615.
19. Andreola G,., Chittenden M, Shaffer J, Cosimi AB, Kawai T, Cotter P, Locascio SA, Morokata T, Dey BR, Tolkoff-Rubin NT, et al. Mechanisms of donor-specific tolerance in recipients of haploidentical combined bone marrow/kidney transplantation. Am J Transplant 2011; 11: 1236-1247.
20. Frohling S, Schlenk RF, Breitruck J, Benner A, Kreitmeier S, Tobis K, Dohner H, Dohner K,; AML Study Group Ulm. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: A study of the AML Study Group Ulm. Blood 2002; 100: 4372-4380.
21. Paschka P, Marcucci G, Ruppert AS, Mrozek K, Chen H, Kittles RA, Vukosavljevic T, Perrotti D, Vardiman JW, Carroll AJ, et al. Adverse prognostic significance of KI mutations in adult acute myeloid leukemia with inv(16) and t(8;21): A Cancer and Leukemia Group B Study. J Clin Oncol 2006; 24: 3904-3911.
22. Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J, Minden M, Paterson B, Caliguri MA, Dick JE,. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994; 367: 645-648.
23. Braun T, Carvalho G, Coquelle A, Vazenin MC, Lepelley P, Hirsch F, Kiladjian JJ, Ribrag V, Fenaux P, Kroemer G,. NF-kappaB constitutes a potential therapeutic target in high-risk myelodysplastic syndrome. Blood 2006; 107: 1156-1165.
24. Guzman ML, Neering SJ, Upchurch D, Grimes B, Howard DS, Rizzieri DA, Luger SM, Jordan CT,. Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood 2001; 98: 2301-2307.
25. Attar EC, Deangelo DJ, Supko JG, D'Amato F, Zahrieh D, Sirulnik A, Wadleigh M, Ballen KK, McAfee S, Miller KB, et al. Phase I and pharmacokinetic study of bortezomib in combination with idarubicin and cytarabine in patients with acute myelogenous leukemia. Clin Cancer Res 2008; 14: 1446-1454.
26. Lasky LC, Lane TA, Miller JP, Lindgren B, Patterson HA, Haley NR, Ballen K,. In utero or ex utero cord blood collection: Which is better? Transfusion 2002; 42: 1261-1267.
27. Rubinstein P,. Cord blood banking for clinical transplantation. Bone Marrow Transplant 2009; 44: 635-642.
28. Chow R, Nademanee A, Rosenthal J, Karanes C, Jaing TH, Graham ML, Tsukahara E, Wang B, Gjertson D, Tan P, et al. Analysis of hematopoietic cell transplants using plasma-depleted cord blood products that are not red blood cell reduced. Biol Blood Marrow Transplant 2007; 13: 1346-1357.
29. Ballen KK, King RJ, Chitphakdithai P, Bolan CD Jr, Agura E, Hartzman RJ, Kernan NA,. The National Marrow Donor Program Experience: The first 20 years of unrelated donor stem cell transplantation. Biol Blood Marrow Transplant 2008; 14: 2-7.
30. Ballen KK, Barker JN, Stewart SK, Greene MF, Lane TA,. Collection and preservation of cord blood for personal use. Biol Blood Marrow Transplant 2008; 14: 356-363.
31. Eapen M, Rubinstein P, Zhang MJ, Camitta BM, Stevens C, Cairo MS, Davies SM, Doyle JJ, Kurtzberg J, Pulsipher MA, et al. Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukemia: A comparison study. Lancet 2007; 369: 1947-1954.
32. Prasad VK, Mendizabal A, Parikh SH, Szabolcs P, Driscoll TA, Page K, Lakshminarayanan S, Allison J, Wood S, Semmel D, et al. Unrelated donor umbilical cord blood transplantation for inherited metabolic disorders in 159 pediatric patients from a single center: Influence of cellular composition of the graft on transplantation outcomes. Blood 2008; 112: 2979-2989.
33. Ruggeri A, Eapen M, Scaravadou A, Cairo MS, Bhatia M, Kurtzberg J, Wingard JR, Fasth A, Lo Nigro L, Ayas M, et al. Umbilical cord blood transplantation for children with thalassemia and sickle cell disease. Biol Blood Marrow Transplant 2011; 17: 1375-1382.
34. Laughlin MJ, Eapen M, Rubinstein P, Wagner JE, Zhang MJ, Champlin RE, Stevens C, Barker JN, Gale RP, Lazarus HM, et al. Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. N Engl J Med 2004; 351: 2265-2275.
35. Ballen KK, Spitzer TR, Yeap BY, McAfee S, Dey BR, Attar E, Haspel R, Kao G, Liney D, Alyea E, et al. Double unrelated reduced-intensity umbilical cord blood transplantation in adults. Biol Blood Marrow Transplant 2007; 13: 82-89.
36. Cutler C, Stevenson K, Kim HT, Brown J, McDonough S, Herrera M, Reynolds C, Liney D, Kao G, Ho V, et al. Double umbilical cord blood transplantation with reduced intensity conditioning and sirolimus based GVHD prophylaxis. Bone Marrow Transplant 2011; 46: 273-277.
37. Chen YB, Aldridge J, Kim HT, Ballen KK, Cutler C, Kao G, Liney D, Bourdeau G, Alyea EP, Armand P, et al. Double umbilical cord blood transplantation (dUCBT) after reduced intensity conditioning (RIC) has similar outcomes compared with RIC transplantation from unrelated adult donors. Biol Blood Marrow Transplant 2012; 18: 805-812.
38. Verneris MR, Brunstein CG, Barker J, MacMillan ML, DeFor T, McKenna DH, Burke MJ, Blazar BR, Miller JS, McGlave PB, et al. Relapse risk after umbilical cord blood transplantation: Enhanced graft-versus-leukemia effect in recipients of 2 units. Blood 2009; 114: 4233-4299.
39. Kindwall-Keller TL, Hegerfeldt Y, Myerson HJ, Margevicius S, Fu P, van Heeckeren W, Lazarus HM, Cooper BW, Gerson SL, Barr P, et al. Prospective study of one- vs two- unit umbilical cord blood transplantation following reduced intensity conditioning in adults with hematological malignancies. Bone Marrow Transplant 2012;47:924-933.
40. Jacobson CA, Turki AT, McDonough SM,. Immune reconstitution after double umbilical cord blood stem cell transplantation: Comparison with unrelated peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 2012; 18: 565-574.
41. Brunstein CG, Weisdorf DJ, DeFor T, Barker TN, Tolar J, van Burik JA, Wagner JE,. Marked increased risk of Epstein-Barr virus-related complications with the addition of antithymocyte globulin to a nonmyeloablative conditioning prior to unrelated umbilical cord blood transplantation. Blood 2006; 108: 2874-2880.
42. Ballen KK, Cutler C, Yeap BY, McAfee SL, Dey BR, Attar EC, Chen YB, Haspel RL, Liney D, Koreth J, et al. Donor-derived second hematologic malignancies after cord blood transplantation. Biol Blood Marrow Transplant 2010; 16: 1025-1031.
43. Boo M, Ballen K, Maiers M,. Cord blood unit access and selection: 2010 and beyond: Best practices and emerging trends in cord blood unit selection. Biol Blood Marrow Transplant 2011; 17: S46-S51.
44. Cutler C, Kim HT, Sun L, Sese D, Glotzbecker B, Armand P, Koreth J, Ho V, Alyea E, Ballen K, et al. Donor-specific anti-HLA antibodies predict outcome in double umbilical cord blood transplantation. Blood 2011; 118: 6691-6697.
45. Eapen M, Klein JP, Sanz G, Spellman S, Ruggeri A, Anasetti C, Brown M, Champlin RE, Garcia-Lopez J, Hattersely G, et al. Effect of donor-recipient HLA matching at HLA A, B, C, and DR B1 on outcomes after umbilical-cord blood transplantation for leukemia and myelodysplastic syndrome: A retrospective analysis. Lancet Oncol 2011; 12: 1214-1226.
46. Lima M, McNiece I, Hosing C, Komanduri K, Worth L, Stabea S, Cooper L, Petropolous D, Lee D, Jones R, et al. Double cord blood transplantation with ex vivo expansion of unit utilizing a mesenchymal stromal platform. Biol Blood Marrow Transplant 2009; 15: 47.
47. Shpall EJ, Bollard CM, Brunstein C, et al. Novel cord blood transplant therapies. Biol Blood Marrow Transplant 2011; 12: S39-S45.
48. Delaney C, Heimfeld S, Brashem-Stein C, Voorhies H, Manger RL, Bernstein ID,. Notch-mediated expansion of human cord blood progenitor cells capable of rapid myeloid reconstitution. Nat Med 2010; 16: 232-236.
49. Cutler CS, Desponts C, Robbins D, North TE, Goesling W, Kao G, Ritz J, Ballen KK, Antin JH, Spitzer TR, et al. Ex vivo treatment of hematopoietic stem cells with 16, 16 dimethyl prostaglandin E2 (FT 1050) improves engraftment and immune reconstitution. Biol Blood Marrow Transplant 2011; 17: 198a.
50. Powles RL, Morgenstern GR, Kay HE, McElwain TJ, Clink HM, Dady PJ, Barrett A, Jameson B, Depledge MH, Watson JG, et al. Mismatched family donors for bone-marrow transplantation as treatment for acute leukemia. Lancet 1983; 1: 612-615.
51. Beatty PG, Clift RA, Mickelson EM, Nisperos BB, Flournoy N, Martin PJ, Sanders JE, Stewart P, Buckner CD, Storb R, et al. Marrow transplantation from related donors other than HLA-identical siblings. N Engl J Med 1985; 313: 765-771.
52. Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A, Posati S, Rogaia D, Frassoni F, Aversa F, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002; 295: 2097-2100.
53. Davies JK, Gribben JG, Brennan LL, Yuk D, Nadler LM, Guinan EC,. Outcome of alloanergized haploidentical bone marrow transplantation after ex vivo costimulatory blockade: Results of 2 phase 1 studies. Blood 2008; 112: 2232-2241.
54. Huang X-J, Liu D-H, Liu K-Y,. Treatment of acute leukemia with unmanipulated HLA-mismatched/haploidentical blood and bone marrow transplantation. Biol Blood Marrow Transplant 2009; 15: 257-265.
55. Brunstein CG, Fuchs EJ, Carter SL, Karanes C, Costa LJ, Wu J, Devine Sm, Wingard JR, Aljitawi OS, Cutler CS, et al. Alternative donor transplantation after reduced intensity conditioning: Results of parallel phase 2 trials using partially HLA- mismatched related bone marrow or unrelated double umbilical cord grafts. Blood 2011; 118: 282-288.
56. Sykes M, Preffer M, McAfee, Saidman SL, Colby C, Sackstein R, Sachs DH, Spitzer TR,. Lasting mixed lymphohematopoietic chimerism is achievable in adult humans following non-myeloablative therapy and HLA-mismatched donor bone marrow transplantation. Lancet 1999; 353: 1755-1756.
57. Spitzer TR, McAfee SL, Dey BR, Colby C, Hope J, Grossberg H, Preffer F, Shaffer J, Alexander SI, Sachs DH, Sykes M,. Nonmyeloablative haploidentical stem-cell transplantation using anti-CD2 monoclonal antibody (MEDI-507)-based conditioning for refractory hematologic malignancies. Transplantation 2003; 75: 1748-1751.
58. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, Thomas ED,. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant 1995; 15: 825-828.
59. Paczesny S, Braun TM, Levine JE, Hogan J, Crawford J, Coffing B, Olsen S, Choi SW, Wang H, Faca V, et al. Elafin is a biomarker of graft-versus-host disease of the skin. Sci Transl Med 2010; 2: 13ra2.
60. Paczesny S, Choi SW, Ferrara JL,. Acute graft-versus-host disease: New treatment strategies. Curr Opin Hematol 2009; 16: 427-436.
61. Chen YB, Kim HT, McDonough S, et al. Up-Regulation of alpha4beta7 integrin on peripheral T cell subsets correlates with the development of acute intestinal graft-versus-host disease following allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2009; 15: 1066-1076.
62. Chen YB, McDonough S, Chen H, Kennedy J, Ballen KK, Dey BR, McAfee SL, Spitzer TR, Jagasia M, Ritz J,. Expression of a4b7 integrin on memory CD8+ T-cells is increased in patients at presentation of acute intestinal graft-vs-host disease. Biol Blood Marrow Transplant 2012; 18: S221.
63. Chen YB, McDonough S, Hasserjian R,. Expression of CD30 in patients with acute graft-vs.-host disease Blood 2012; June 1 [Epub ahead of print].
64. Cutler C, Antin JH,. Sirolimus immunosuppression for graft-versus-host disease prophylaxis and therapy: An update. Curr Opin Hematol 2010; 17: 500-504.
65. Luznik L, Jones RJ, Fuchs EJ,. High-dose cyclophosphamide for graft-versus-host disease prevention. Curr Opin Hematol 2010; 17: 493-499.
66. Bensinger WI,. Allogeneic transplantation: Peripheral blood vs. bone marrow. Curr Opin Oncol 2012; 24: 191-196.
67. Anasetti C, Logan BR, Lee SJ, Waller EK, Weisdorf DJ, Wingard JR, Cutler CS, Westervelt P, Woolfrey A, Couban S, et al. Increased incidence of chronic graft-versus-host disease and no survival advantage with filgrastim-mobilized peripheral blood stem cells compared to bone marrow transplants from unrelated donors: Results of Blood and Marrow Transplant Clinical Trials Network Protocol 0201, a phase III, prospective, randomized trial. Blood 2011; 118: 368.
68. Lee SJ, Flowwers ME,. Recognizing and treating chronic graft-versus-host disease. Hematology Am Soc Hematol Educ Program 2008: 134-141.
69. Ringden O, Karlsson H, Olsson R, Omazic B, Uhlin M,. The allogeneic graft-versus-cancer effect. Br J Haematol 2009; 147: 614-633.
70. Filipovich AH, Weisdorf D, Pavletich S, Socie G, Wingard JR, Lee SJ, Martin P, Chien J, Prezepiorka D, Couriel D, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: Diagnosis and staging working report. Biol Blood Marrow Transplant 2005; 11: 945-956.
71. Kharfan-Dabaja MA, Cutler CS,. Rituximab for prevention and treatment of graft-versus host disease. Int J Hematol 2011; 93: 578-585.
72. Greinix HT, van Besien K, Elmagachi AH, Hillen U, Grigg A, Knobler R, Parenti D, Reddy V, Theunissen K, Michallet M, Flowers ME., Progressive improvement in cutaneous and extracutaneous chronic graft-versus-host disease after a 24 week course of extracorporeal photopheresis-results of a crossover randomized study. Biol Blood Marrow Transplant 2011; 17: 1775-1782.
73. Koreth J, Matsuoka K, Kim HT, McDonough SM, Bindra B, Alyea EP 3rd, Armand P, Cutler C, Ho VT, Treister NS, et al. Interleukin-2 and regulatory T cells in graft- versus- host disease. N Engl J Med 2011; 365: 2055-2066.
74. Gooley TA, Chien JW, Pergam SA, Hingorani S, Sorror ML, Boeckh M, Martin PJ, Sandmaier BM, Marr KA, Appelbaum FR, et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med 2011; 363: 2091-2101.